Pharmacological Management of No Reflow During Percutaneous Coronary Intervention

By  

Current Vascular Pharmacology, Vol. 4, Iss. 2, 2006-04 ,pp. : 95-100

Bentham Science Publishers

Access to resources Recommend Favorite

Percutaneous Coronary Intervention in Diabetics

By Karha Juhana   Bhatt Deepak L.  

Reviews in Endocrine and Metabolic Disorders, Vol. 5, Iss. 3, 2004-08 ,pp. : 277-285

Springer Publishing Company

Access to resources Recommend Favorite

Distal myocardial protection during percutaneous coronary intervention with an intracoronary -blocker

By Wang F.W.   Osman A.   Otero J.  

ACC Current Journal Review, Vol. 12, Iss. 5, 2003-09 ,pp. : 56-57

Elsevier

Access to resources Recommend Favorite

Prasugrel During Primary Percutaneous Coronary Intervention: Evidence from Clinical Data

By  

Current Vascular Pharmacology, Vol. 10, Iss. 4, 2012-07 ,pp. : 454-457

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical introduction of the Tandemheart, a percutaneous left ventricular assist device, for circulatory support during high-risk percutaneous coronary intervention

By Vranckx Pascal   Foley David P   Feijter Pim J de   Vos Jeroen   Smits Peter   Serruys Patrick W  

International Journal of Cardiovascular Interventions, Vol. 5, Iss. 1, 2003-01 ,pp. : 35-39

Informa Healthcare

Access to resources Recommend Favorite